Allogeneic blood stem cell transplantation in advanced hematologic cancers

D. Przepiorka, P. Anderlini, C. Ippoliti, I. Khouri, T. Fietz, P. Thall, R. Mehra, S. Giralt, J. Gajewski, A. B. Deisseroth, K. Cleary, R. Champlin, K. Van Besien, B. Andersson, M. Körbling

    Research output: Contribution to journalArticle

    80 Scopus citations

    Abstract

    Allogeneic bone marrow transplantation for advanced hematologic cancer is associated with a high risk of early treatment-related morbidity and mortality. To determine the short-term benefits of allogeneic blood stem cell transplants when compared to bone marrow transplants, we reviewed outcomes of 74 adults with advanced hematologic cancer transplanted from HLA-matched related donors after conditioning with thiotepa, busulfan and cyclophosphamide. There were three cohorts: group 1 received bone marrow transplants with cyclosporine (CsA) and methotrexate (MTX) for GVHD prophylaxis; group 2 received bone marrow transplants with CsA and methylprednisolone (MP); and group 3 received blood stem cells with CsA and MP. All patients received filgrastim post-transplant, Median times (range) to neutrophils ≤ 0.5 x 109/l were 17 (8-30), 9 (8-16) and 10 (8-13) days post-transplant, and to platelets ≤ 20 x 109/l were 28 (14-100+), 19 (13-100+) and 14 (9-86) days post-transplant for groups 1, 2 and respectively (P < 0.05 only for group 1 vs group 3 for both outcomes). Blood stem cell recipients had the least regimen-related toxicity, fewest early deaths and earliest discharge. There was no significant difference acute GVHD between the three groups. One hundred and eighty-day survivals (95% CI) were 53% (35-72%), 32% (10-53%), and 68% (49-87%) for groups 1, 2 and 3, respectively (P < 0.05 only for group 2 vs group 3). For allogeneic transplantation, use of blood stem cell grafts has substantial advantages over marrow grafts.

    Original languageEnglish (US)
    Pages (from-to)455-460
    Number of pages6
    JournalBone marrow transplantation
    Volume19
    Issue number5
    DOIs
    StatePublished - Mar 1 1997

    Keywords

    • Allogeneic blood stem cell transplant
    • Leukemia
    • Treatment-related mortality

    ASJC Scopus subject areas

    • Hematology
    • Transplantation

    Fingerprint Dive into the research topics of 'Allogeneic blood stem cell transplantation in advanced hematologic cancers'. Together they form a unique fingerprint.

  • Cite this

    Przepiorka, D., Anderlini, P., Ippoliti, C., Khouri, I., Fietz, T., Thall, P., Mehra, R., Giralt, S., Gajewski, J., Deisseroth, A. B., Cleary, K., Champlin, R., Van Besien, K., Andersson, B., & Körbling, M. (1997). Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone marrow transplantation, 19(5), 455-460. https://doi.org/10.1038/sj.bmt.1700692